Search - tctmd.com

Displaying 161 - 180 of 210

Sort: Relevancy | Date

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

September 24, 2018

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

New Review Probes Possibility of CVD Prevention Without Aspirin

News Daily News

New Review Probes Possibility of CVD Prevention Without Aspirin

Michael O'Riordan

July 04, 2018

NAVIGATE ESUS: Rivaroxaban Fails to Prevent More Recurrent Cryptogenic Strokes Than Aspirin

News Daily News

NAVIGATE ESUS: Rivaroxaban Fails to Prevent More Recurrent Cryptogenic Strokes Than Aspirin

May 16, 2018

Spin to Win: Results From Late Breaking Meeting Trials Often Overstated

News Daily News

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

May 15, 2018

EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms

News Conference News EAS 2018

EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms

Yael L. Maxwell

May 11, 2018

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

News Daily News

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Michael O'Riordan

April 25, 2018

Time for Guidelines to Recommend ARBs Over ACE Inhibitors?

News Daily News

Time for Guidelines to Recommend ARBs Over ACE Inhibitors?

March 29, 2018

Aspirin Switch for VTE Prevention After Hip/Knee Arthroplasty: Safe, Effective, and Cost-Saving in EPCAT II

News Daily News

Aspirin Switch for VTE Prevention After Hip/Knee Arthroplasty: Safe, Effective, and Cost-Saving in EPCAT II

Michael O'Riordan

February 21, 2018

Nonstatin Use and Expenditures Are Up Despite the Dearth of Evidence Supporting Efficacy

News Daily News

Nonstatin Use and Expenditures Are Up Despite the Dearth of Evidence Supporting Efficacy

Yael L. Maxwell

January 29, 2018

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

November 14, 2017

Statins and Diabetes: Causal Link Reinforced in New Analysis

News Daily News

Statins and Diabetes: Causal Link Reinforced in New Analysis

Michael O'Riordan

October 25, 2017

Acute MI Patients With Cancer History Less Likely to Get Evidence-Based Therapies

News Daily News

Acute MI Patients With Cancer History Less Likely to Get Evidence-Based Therapies

September 25, 2017

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

September 15, 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

News Conference News ESC 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

August 30, 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Industry News

RE-DUAL PCI™ Results Offer Favorable New Safety Data on Pradaxa®

August 28, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

Evolocumab Not Cost-Effective at Current List Price

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.